On May 22, one of the global leading peptide suppliers Creative Peptides announced to release HIV related peptides, a new product line, for scientists who are engaged in the HIV research. Previously Creative Peptides already provides unique peptides for research related to Alzheimer’s disease, cancer, diabetes, immunotherapy & cell therapy, etc.
HIV (human immunodeficiency virus) harms the immune system by destroying the white blood cells that fight infection. People being infected by this virus are often at risk of getting serious infections and certain cancers, with AIDS being the worst case in the final stage. The cause are pathogens such as Candida, Mycobacterium tuberculosis or latent herpesvirus (such as EBV, HCMV). After 30 years of the discovery of HIV-1/AIDS, an estimated 33 million people were infected with this virus and the majority died from the disease. So how to treat and control this disease is of paramount importance for the research circle.
Although a cure for HIV does not yet exist, an antiretroviral therapy (ART) is widely recommended all people diagnosed with HIV, especially by the U.S. Department of Health and Human Services, to effectively put the virus under control. In designing a new strategy for the treatment of HIV-1 infection, one epicenter is the synergistic effect of peptide chemistry and structural biology. A milestone in AIDS treatment is the approval of the first peptide fusion inhibitor.
“Therapeutic peptides and proteins as HIV-1 inhibitors are gradually becoming an alternative strategy for HIV-1 treatment because of their diverse advantages like high specificity and affinity to their molecular targets. In most cases, HIV-1 mutants are difficult to avoid these molecules,” explains the Product Manager at Creative Peptides. “Peptide chemists are already very familiar with the concept of targeting peptides to membranes to increase receptor interactions. Surprisingly, these peptides seem to be able to prevent viruses from entering in a variety of ways through working in different mechanisms. As an additional advantage, such anti-HIV peptides may also have antibacterial, anti-parasite, spermicidal, and anticancer activities. So it is believed in the research circle that with the continuous optimization of peptide stability, production, preparation and release methods, some of these compounds are expected to eventually become new anti-HIV drugs.”
The HIV related peptides newly launched at Creative Peptides include: HIV-1 gag Protein Fragments, HIV Protease Substrates and inhibitors, CONSENSUS B Tat Fragments, GP120-W61D Fragments, HIV-1 CONSENSUS B VIF Fragments, HIV-1 MN ENV Fragments, HIV-1 MN gp160 Fragment, HXB2 gag NO Fragments, SIVmac239 Fragments, HIV-1 rev and tat fragments, HIV-1 MN NO Fragment, and more.
For more information about HIV related peptides, please visit: https://www.creative-peptides.com/research-areas/hiv-related-peptides.html.
About author
Creative Peptides is a US-based expert aimed at creating a better and healthier world for the human beings, altogether with other industries. It keeps enriching its peptide related product and services in the last decade, with a supply range covering checkpoint inhibitors, therapeutic peptides, cosmetic peptides, catalog peptides as well as the modification, synthesis, analysis services of peptides, such as Cyclic Peptide synthesis, Amino Acids Modification, Stapled Peptide Synthesis, Long Peptides Synthesis, Oligopeptide Synthesis, Post-translational Modification, Peptide Drug Discovery, Peptide Lead Optimization.
Media Contact
Company Name: Creative Peptides
Contact Person: Cathy Miller
Email: Send Email
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
State: NY
Country: United States
Website: www.creative-peptides.com